Enhertu Gets US Approval for 1st-Line HER2+ Breast Cancer
Ticker: AZN · Form: 6-K · Filed: Dec 16, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Dec 16, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 11 min |
| Key Dollar Amounts | $150m |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-approval, oncology, breast-cancer, regulatory-filing
TL;DR
AstraZeneca's Enhertu approved for 1st-line HER2+ breast cancer in the US.
AI Summary
AstraZeneca PLC announced on December 16, 2025, that its drug Enhertu has received US approval for first-line treatment of HER2-positive metastatic breast cancer. This approval expands the use of Enhertu, a collaboration with Daiichi Sankyo, to a new patient population.
Why It Matters
This expanded indication for Enhertu could significantly increase its market potential and provide a new, earlier treatment option for a substantial number of breast cancer patients.
Risk Assessment
Risk Level: low — This is a routine regulatory filing announcing an approved drug indication, which is generally positive news.
Key Players & Entities
- AstraZeneca PLC (company) — Registrant
- Enhertu (drug) — Approved medication
- Daiichi Sankyo (company) — Collaboration partner for Enhertu
- December 16, 2025 (date) — Date of announcement
- US (location) — Jurisdiction of approval
FAQ
What is the specific indication for which Enhertu received US approval?
Enhertu received US approval for the first-line treatment of HER2-positive metastatic breast cancer.
Who is AstraZeneca's partner for the drug Enhertu?
AstraZeneca's partner for Enhertu is Daiichi Sankyo.
On what date was this announcement filed with the SEC?
This Form 6-K was filed on December 16, 2025.
What is AstraZeneca's primary business sector?
AstraZeneca PLC is in the Pharmaceutical Preparations sector, SIC code 2834.
Does AstraZeneca file annual reports under Form 20-F?
Yes, AstraZeneca indicates it files annual reports under Form 20-F.
Filing Stats: 2,856 words · 11 min read · ~10 pages · Grade level 13.2 · Accepted 2025-12-16 06:19:51
Key Financial Figures
- $150m — val   in the US, an amount of $150m is due from AstraZeneca to Daiichi Sank
Filing Documents
- a6719l.htm (6-K) — 64KB
- 0001654954-25-013970.txt ( ) — 65KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC   Date: 16 December 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary